

****Published September 2015****

MarketVIEW: Biodefense vaccines (CAT: VAMV063)

Product Name	:	MarketVIEW: biodefense vaccines
Description	:	Global vaccine overview
Contents	:	Executive presentation (.pdf)
Therapeutic Area	:	Existing vaccines
Publication date	:	September 2015
Catalogue No	:	VAMV063

Background

Since the 2001 terrorist attacks and continued threats at a global level against many Western governments, the concept of **biodefense** has become an important component of many national countermeasure strategies. To this end, a number of chemical, biological¹, radiological, and nuclear (CBRN) terrorism agents were identified as part of a new US law passed in 2004 known as the Project Bioshield Act. This act allowed the US government to guarantee a market for CBRN countermeasures, which up until June 2014 obligated approximately \$3.309 bn in funding.

Despite Project Bioshield and The Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (PAHPRA), which has effectively extended the Project BioShield procurement program to FY2018, the US HHS has obligated 90% to just three threats: anthrax, smallpox, and botulinum toxin. Project BioShield did not acquire any countermeasures against the other eight material CBRN threats, meaning that a significant amount of research and development is still required.

The **MarketVIEW** report covers in depth the background, legislation and current US capabilities with regard to biodefense vaccines with a focus on anthrax, smallpox and other biodefense vaccines. For anthrax and smallpox, detailed coverage is provided on disease epidemiology, past and current vaccines/associated recommendations/policy and corporate development of new generation vaccines for inclusion to the future US Strategic National Stockpile. The objective of this report is to give the reader a full background into the biodefense industry so that future dynamics/trends can be visualized for potential strategy development or market entry.

¹ *Bacillus anthracis* and multi-drug resistant *Bacillus anthracis*, *Burkholderia mallei*, *Burkholderia pseudomallei*, Botulinum toxins, Ebola virus, *Francisella tularensis*, Junin virus, Marburg virus, *Rickettsia prowazekii*, Variola virus, *Yersinia pestis*

Methodology

VacZine Analytics has closely monitored all significant source material pertaining biodefence vaccines and related pathogens e.g. smallpox, anthrax. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of novel vaccines has also been utilised.

PRODUCT CONTENTS:

Published September 2015 (CAT No: VAMV063)

****This product is composed of a summary presentation (.pdf) only

Author's note
Contents
Executive summary
Summary table of biodefence vaccines
Authors note
What is biodefense?
Key events in US biodefense policy
The US Project Bioshield Act
CBRN Agents Determined to Pose a Material Threat
Use of FY2004-FY2013 advance appropriations (\$m)
Project BioShield Acquisition Activity
Project BioShield Countermeasure Acquisition by Threat FY2004-FY2014 (\$m)
The Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (PAHPRA)
Other important US Biodefense legislation
Biomedical Advanced Research and Development Authority (BARDA)
BARDA - progress since 2004
Attributes of biodefense vaccines
Technology support to biodefense vaccines (US BARDA)
Next generation concepts (US BARDA)
Biodefense vaccines: US Capabilities
US HHS Centers for Innovation in Advanced Development and Manufacturing (CIADMs)
CIADM: Texas A&M University System (TAMUS)
CIADM: ex-Novartis Vaccines and Diagnostics, Cambridge MA
CIADM: Emergent Biosolutions, Gathersburg, MD
CIADMs - summary map
US Department of Defense (DoD) - CBD program
Biodefense vaccines: anthrax
Anthrax: disease background
Types of anthrax
Anthrax: US incidence
Anthrax and bioterrorism
Anthrax: management (general)
History of anthrax vaccines: US
History of anthrax vaccines: detailed timeline
Anthrax vaccine: recommended groups (ACIP - 2009)

Continued.....

Focus on AVA vaccine: Biothrax pre-exposure schedule
Anthrax: Post-exposure prophylaxis (PEP)
Anthrax vaccines: current and future research
HHS PHEMCE anthrax programmatic priorities
Next generation Anthrax vaccines: NuThrax™
Next generation Anthrax vaccines: PreviThrax™
Next generation Anthrax vaccines: Soligenix
Ad5 Vectored Anthrax vaccine - NasoShield (VAXIN)
Pfenex Inc (Px563L)
PharmAthene: SparVax rPA Anthrax Vaccine
Market for Anthrax vaccines
Anthrax supply contracts: Emergent Biosolutions
Emergent Biosolutions: product sales 2012 - 2014, Biothrax
Emergent Biosolutions – spinout
Biodefense vaccines: smallpox
Smallpox: disease background
Types of smallpox
Smallpox disease symptoms
Vaccination and smallpox
Conventional smallpox vaccines
WHO smallpox eradication campaign
Smallpox: six preconditions for eradication met
Smallpox vaccines and biodefense
Smallpox as a weapon: former USSR
Global smallpox vaccine stockpiles (2005)
Second generation smallpox vaccines
Third generation smallpox vaccines
Bavarian Nordic: MVA-BN
MVA-BN and US Project Bioshield
Bavarian Nordic: US contracts awarded to date
MVA-BN and Canada/EU/ROW
IMVANEX: revenue potential at high threat level
IMVAMUNE: life cycle management
Other key vaccines: Kaketsuken Japan: LC16m81
History of Smallpox Vaccine Preparedness in Japan
Kaketsuken Japan: LC16m8 - US BARDA program
Other biodefense vaccines
Botulinum toxin vaccine
Tularemia vaccines
Ricin vaccines
Burkholderia vaccines
Alphaviruses and biodefense vaccines
Bibliography
About **VacZine Analytics**
Disclaimer

PAGES: ~90 slides, fully referenced/sourced. Available in .pdf form

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **\$5995.00**/ GBP **£3865.00*** (Region license)*

Indicative rate only. Prevailing rate applied to date of transaction.

*A region is North America, Europe or ROW

For orders in the UK, VAT at 20.0% will be added to final invoice total

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and the “spiral logo” are UK Registered Trademarks, 2009

BIBLIOGRAPHY

1. The Project Bioshield Act: Issues for the 113th Congress. By Frank Gotton (June 2014). Congressional Research Service
2. US Department of Health and Human Services. BARDA unveils path forward in the BARDA Strategic Plan 2011-2016. Available at: <http://www.phe.gov/about/barda/Pages/2011barda-stratplan.aspx>. Accessed June 2015
3. Renewing the Project Bioshield Act. What has it Brought and Wrought? Policy Brief. Center for a New American Security. January 2013
4. US Department of Human and Health Services. Fact sheet. Centers for Innovation in Advanced Development and Manufacturing (CIADM). Available at: https://www.medicalcountermeasures.gov/media/8862/aspa_0420_20120615_aspr_pr_countermeasures_fact_sheet_combined508.pdf. Accessed August 2015
5. US Department of Human and Health Services. TAMUS Fact sheet. Centers for Innovation in Advanced Development and Manufacturing (CIADM). Available at: https://www.medicalcountermeasures.gov/media/8871/aspa_0420_20120615_aspr_pr_countermeasures_fact_sheet_tamus508.pdf. Accessed August 2015
6. US Department of Human and Health Services. Novartis Fact sheet. Centers for Innovation in Advanced Development and Manufacturing (CIADM). Available at: https://www.medicalcountermeasures.gov/media/36752/aspa_0420_20120615_aspr_pr_countermeasures_fact_sheet_novartis_v02_-_508.pdf. Accessed August 2015
7. US Department of Human and Health Services. Novartis Fact sheet. Centers for Innovation in Advanced Development and Manufacturing (CIADM). Available at: https://www.medicalcountermeasures.gov/media/8865/aspa_0420_20120615_aspr_pr_countermeasures_fact_sheet_emergent508.pdf. Accessed August 2015
8. US Department of Human and Health Services. Map. Fact sheet. Centers for Innovation in Advanced Development and Manufacturing (CIADM). Available at: https://www.medicalcountermeasures.gov/media/34653/ciadm_map_1aug2013_508.pdf. Accessed August 2015
9. 2014 Department of Defense Chemical and Biological Defense Annual Report to Congress. Department of Defense Chemical and Biological Defense Program. March 2014
10. Nanotherapeutics to create 150 jobs at new Alachua manufacturing facility. April 2013. Available at: <http://www.gainesvillechamber.com/2013/04/nanotherapeutics-to-create-150-jobs-at-new-alachua-manufacturing-facility/>. Accessed August 2015
11. PharmAthene and Nanotherapeutics Form Strategic Alliance to Advance Biodefense Programs. Sept 2014. Available at: <http://ir.pharmathene.com/phoenix.zhtml?c=191999&p=irol-newsArticle&ID=1964759>. Accessed August 2015
12. US Centers For Disease Control and Prevention. CDC. Basics – what is anthrax? Available at: <http://www.cdc.gov/anthrax/basics/index.html>. Accessed June 2015
13. Diseases and conditions. Anthrax. Definition. Available at: <http://www.mayoclinic.org/diseases-conditions/anthrax/basics/definition/con-20022705>. Accessed June 2015
14. US Centers For Disease Control and Prevention. CDC. Basics – what is anthrax? Available at: <http://www.cdc.gov/anthrax/basics/index.html>. Accessed June 2015
15. US Centers For Disease Control and Prevention. CDC. Basics – what is anthrax? Available at: <http://www.cdc.gov/anthrax/basics/index.html>. Accessed June 2015
16. Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009
17. Rotz LD, Khan AS, Lillibridge SR, Ostroff SM, Hughes JM. Public health assessment of potential biological terrorism agents. *Emerg Infect Dis* 2002;8:225–30
18. Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outbreak of 1979. *Science* 1994;266:1202–8.
19. World Health Organization. Health aspects of chemical and biological weapons: a report of a WHO group of consultants. Geneva, Switzerland: World Health Organization; 1970.
20. Office of Technology Assessment; US Congress. Proliferation of weapons of mass destruction. Publication OTA-ISC-559, no. 53-55. Washington, DC: Government Printing Office; 1993:53–5.
21. Tigertt WD. Anthrax. William Smith Greenfield, M.D., F.R.C.P, Professor Superintendent, the Brown Animal Sanatory Institution (1878–81). Concerning the priority due to him for the production of the first vaccine against anthrax. *J Hyg (Lond)* 1980;85:415–20.
22. Brachman PS, Gold H, Plotkin SA, Fekety FR, Werrin M, Ingraham NR. Field evaluation of a human anthrax vaccine. *Am J Public Health Nations Health* 1962;52:632–45.
23. Anthrax vaccine adsorbed. United States patent US 3208909. September 28, 1965.

24. Food and Drug Administration. Investigational New Drug (IND) application: development and approval process. Accessed October 27, 2009. Available at <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/default.htm>.
25. Anthrax Vaccine: GAO's survey of Guard and Reserve Pilots and Aircrew. September 2002. United States General Accounting Office. Available at: <http://www.gao.gov/new.items/d02445.pdf>. Accessed July 2015
26. Meyerhoff A, Albrecht R, Meyer JM, Dionne P, Higgins K, Murphy D. U.S. Food and Drug Administration approval of ciprofloxacin hydrochloride for management of postexposure inhalational anthrax. *Clin Infect Dis* 2004;39:303--8.
27. Food and Drug Administration. Prescription drug products: doxycycline and penicillin G procaine administration for inhalational anthrax (post-exposure). *Federal Reg* 2001;66:55679--82.
28. Shepard CW, Soriano-Gabarro M, Zell ER, et al. Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence. *Emerg Infect Dis* 2002;8:1124--32.
29. Inglesby TV et al. Working Group on Civilian Biodefense. 2002. Anthrax as a biological weapon, 2002: updated recommendations for management. *JAMA* 287:2236--2252
30. US Department of Health and Human Services. 2014 Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Strategy and Implementation Plan
31. Soligenix Corporate Website. July 2015. Available at: http://www.soligenix.com/prod_def_sgx204.shtml. Accessed July 2015
32. Soligenix Announces Publication Successfully Demonstrating Enhanced Immunogenicity of its Heat-Stable Anthrax Vaccine
33. Zhang J et al. An Adenovirus-Vectored Nasal Vaccine Confers Rapid and Sustained Protection against Anthrax in a Single-Dose Regimen *Clin Vaccine Immunol*. 2013 Jan; 20(1): 1--8.
34. Krishnan et al. Efficacy and Immunogenicity of Single-Dose AdVAV Intranasal Anthrax Vaccine Compared to Anthrax Vaccine Absorbed in an Aerosolized Spore Rabbit Challenge Model. *Clin Vaccine Immunol* April 2015 vol. 22 no. 4 430-439
35. First Responders. Understanding The Role of First Responders and How Their Partnership With the Federal Government Is Vital To Protecting Americans and Saving Lives. Presentation by Christopher Cox, Select Committee on Homeland Security
36. Emergent Biosolutions. United States – Security and Exchange Commission. Washington, D.C. 20549. Form 10-K for the fiscal year ended 2014
37. Emergent Biosolutions Corporate Press Release. August 6th 2015. Available at: <http://emergentbiosolutions.com/news?page=releasetxt&id=2076514&pubdate=August%2006%2C%202015>. Accessed August 2015
38. US Centres for Disease Control and Prevention. Smallpox Disease Overview. Available at: <http://www.bt.cdc.gov/agent/smallpox/overview/disease-facts.asp>. Accessed August 2015
39. World Health Organisation: Smallpox. Available at: <http://www.who.int/csr/disease/smallpox/en/>. Accessed August 2015
40. Emedicine Health. Smallpox causes. Available at: http://www.emedicinehealth.com/smallpox/page2_em.htm. Accessed August 2015
41. Kennedy RB et al. Smallpox vaccines for Biodefense. *Vaccine* 2009 Nov 5; 27S4: D73-D79
42. Center for global development. Case I: eradicating small pox. Available at: <http://www.cgdev.org/page/case-1-eradicating-smallpox>. Accessed August 2015
43. Artenstein AW et al. Smallpox Vaccines for Biodefense: Need and Feasibility. *Expert Review of Vaccines*. 2008; 7(8):1225-1237
44. Arita I. Smallpox vaccine and its stockpile in 2005. *The Lancet infectious diseases* Oct;2005 5(10): 647--52
45. Alibek K. *Biohazard*. New York. NY. Random House Inc 1999
46. Henderson DA et al. Smallpox as a biological weapon. *Medical and Public Health Management*. *JAMA* 1999: 2127-2137
47. National Smallpox vaccine stockpiles. Atlantic Storm analysis. 14th January 2005. Available at: http://www.upmchealthsecurity.org/our-work/events/2005_atlantic_storm/flash/pdf/update_1000.pdf. Accessed August 2005
48. ACAM2000 Smallpox (vaccinia) vaccine, live package insert www.fda.gov/Cber/label/acam2000LB.pdf (Accessed June, 2008)
49. FDA approves second-generation smallpox vaccine www.fda.gov/bbs/topics/NEWS/2007/NEW01693.html (Accessed April, 2008)
50. Henderson DA, Inglesby TV, Bartlett JG *et al*. Smallpox as a biological weapon. *JAMA* 281, 2127-2137 (1999)
51. Bavarian Nordic Corporate Website. MVA-BN. Available at: <http://www.bavarian-nordic.com/what-we-do/technologies/mva-bn.aspx>. Accessed August 2015
52. The Project Bioshield Act: Issues for the 113th Congress. By Frank Gotton (June 2014). Congressional Research Service
53. Bavarian Nordic. Interim Financial Report. Jan 1 – March 31, 2015. Available at: <http://www.bavarian-nordic.com/media/190207/2015-q1-uk.pdf>. Accessed August 2015
54. Bavarian Nordic Corporate presentation. June 15, 2015. Available at: <http://www.bavarian-nordic.com/media/192047/150615-citi-en.pdf>. Accessed August 2015

55. Bavarian Nordic Corporate Press Release. August 26th 2014. Available at: <http://globenewswire.com/news-release/2014/08/26/661130/0/en/Bavarian-Nordic-Receives-Order-from-the-Canadian-Government-to-Supply-IMVAMUNE-Smallpox-Vaccine.html>. Accessed August 2015
56. Bavarian Nordic. US Imvamune Contract confirmed. ADR Research H114 results
57. Medical countermeasures against smallpox and botulism. A presentation by Hiroyukii Yokote. Kaketsuken (Chemo-Sero-Therapeutic Research Institute)
58. M. Yamaguchi, et al. Vaccination research group research report: Ministry of Health and Welfare special research: post-vaccination side effects and research regarding treatment of complications. Rinsho to Uirusu 1975, 3: 269-79
59. Saito, T. et al. Clinical and immunological response to attenuated tissue-cultured smallpox vaccine. LC16m8.JAMA 2009;301:1025-1033
60. T Saito et al. Research on Preparedness for Bioterrorism - Associated Events in Japan: Smallpox Vaccine Preparedness Journal of Disaster Research, Vol.4, No.5 pp. 329-336, 2009
61. Kaketsuken (Chemo-Sero-Therapeutic Research Institute). KAKETSUKEN Awarded HHS Contract Valued at up to \$34 Million for the Development of a Live Attenuated Smallpox Vaccine (LC16m8). January 12, 2011. Press release.
62. Notice of CDC's Discontinuation of Investigational Pentavalent (ABCDE) Botulinum Toxoid Vaccine for Workers at Risk for Occupational Exposure to Botulinum Toxins. MMWR Weekly October 28, 2011. 60 (42);1454-1455
63. Byrne, M. P., and L. A. Smith. 2000. Development of vaccines for prevention of botulism. Biochemie 82:955-966
64. Byrne, M. P., T. J. Smith, V. A. Montgomery, and L. A. Smith. 1998. Purification, potency and efficacy of a botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect. Immun. 66:4817-5011
65. Smith, L. A., and J. M. Rusnak. 2007. Botulinum neurotoxin vaccines: past present and future. Crit. Rev. Immunol.
66. Dennis DT et al. Tularemia as a Biological Weapon. Medical and Public Health Management. JAMA June 6, 2001 Vol 285, No 21
67. NIH News. October 3rd 2005. Large Tularemia Vaccine Contracts Among New NIAID Biodefense Awards.
68. Marohn ME et al. Live attenuated tularemia vaccines: recent developments and future goals. Vaccine. 2013 Aug 2; 31 (35): 3485-91
69. Roy et al. Thermostable ricin vaccine protects rhesus macaques against aerosolized ricin: Epitope-specific neutralizing antibodies correlate with protection. PNAS. 3782-3787 March 24th 2015 Vol 112 No 12
70. Vitetta et al., 2006, PNAS, 105:2268-2273
71. Vitetta et al., 2012, Recombinant Ricin Vaccine Phase 1B Clinical Trial, Clin. Vaccine Immunol. 10:1697-9
72. Silva EB et al. Development of Burkholderia mallei and pseudomallei vaccines. Cellular and Infection Microbiology. 11th March 2013
73. Corporate News Release. Bavarian Nordic to Develop Biodefence Vaccine. February 24th 2014. Available at: <http://globalbiodefense.com/2014/02/24/bavarian-nordic-to-help-develop-biodefense-vaccine/>. Accessed August 2015
74. Spurgers KB et al. Vaccine development for Biothreat Alphaviruses. J Bioterr Biodef 2011, S1
75. Pittman PR. Long term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine following booster administration with inactivated VEEV vaccine. Vaccine 1996; 14:337-343

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009